Circulating angiotensin converting enzyme 2 activity as a biomarker of silent atherosclerosis in patients with chronic kidney disease
Soler, María José
MetadataShow full item record
Abstract BACKGROUND AND AIMS: Circulating Angiotensin Converting Enzyme 2 (ACE2) activity in chronic kidney disease (CKD) patients without previous history of cardiovascular disease (CVD) has been associated with classical risk factors (older age, diabetes and male gender). Furthermore, silent atherosclerosis has been described as a pathological link between CKD and CVD. We analyzed baseline ACE2 activity in non-dialysis CKD stages 3-5 (CKD3-5) patients as a biomarker of renal progression, silent atherosclerosis and CV events after 2 years of follow-up. METHODS: Prospective study of 1458 CKD3-5 subjects without any previous CV event included in the Spanish multicenter NEFRONA study. Association between baseline circulating ACE2 activity and renal parameters, carotid/femoral echography, atheromatous disease, ankle-brachial index, intima-media thickness, need of renal replacement therapy, cardiovascular events and mortality at 24 months of follow-up were analyzed. RESULTS: Patients with an increase in the number of territories with plaques at 24 months showed significantly higher levels of baseline ACE2 activity as compared to stable patients (29.6 (20.6-47.6)RFU/μL/h versus 35.7 (24.5-56), p < 0.001). Multivariate linear regression analysis showed that male gender, pathological ankle-brachial index and progressive silent atherosclerosis defined as an increased number of territories with plaques at 24 months were associated with increased baseline ACE2 activity. Male gender, older age, diabetes, smoking and increased baseline circulating ACE2 were independent predictors of atherosclerosis at 24 months of follow-up. CONCLUSIONS: In CKD3-5 patients, higher circulating ACE2 activity at baseline is associated with higher risk for silent atherosclerosis, suggesting that ACE2 may serve as a biomarker to predict CV risk before CVD is established.
Is part ofAtherosclerosis, 2016, vol. 253, p. 135-143
European research projects
Showing items related by title, author, creator and subject.
Cardiovascular risk factors and the impact on prognosis in patients with chronic kidney disease secondary to autosomal dominant polycystic kidney disease Gorriz, Jose L.; Arroyo, David; D’Marco, Luis; Torra, Roser; Tomás, Patricia; Puchades, María Jesús; Panizo, Nayara; Pantoja, Jonay; Montomoli, Marco; Llisterri, José Luis; Pallares Carratalá, Vicente; Valdivielso Revilla, José Manuel (BMC, 2021)Background: Autosomal dominant polycystic kidney disease (ADPKD) is the most frequent hereditary renal disease. There is an increased rate of cardiovascular disease (CVD) in ADPKD. In this study, we evaluate the prevalence ...
Lorca, Cristina; Mulet, Maria; Arévalo Caro, Catalina; Sánchez, M. Ángeles; Pérez, Ainhoa; Perrino, María; Bach Faig, Anna; Aguilar Martínez, Alicia; Vilella, Elisabet; Gallart-Palau, Xavier; Serra Maqueda, Aida (Taylor & Francis, 2022)Substances with modulatory capabilities on certain aspects of human cognition have been revered as nootropics from the dawn of time. The plant kingdom provides most of the currently available nootropics of natural origin. ...
Usefulness of imaging techniques and novel biomarkers in the prediction of cardiovascular risk in patients with chronic kidney disease in Spain: The NEFRONA project Junyent, Mireia; Martínez Alonso, Montserrat; Borràs, Mercè; Betriu i Bars, M. Àngels; Coll, Blai; Craver Hospital, Lourdes; Marco Mayayo, M. Paz; Sarró, Felipe; Valdivielso Revilla, José Manuel; Fernández i Giráldez, Elvira (Sociedad Española de Nefrologia, 2010)Background: Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in patients with chronic kidney disease (CKD). Cardiovascular risk assessment in this population is hampered by the failure of ...